Implant Renal Injury-Responsive Cells to Supplement Erythropoietin and Protect Kidney Injury

Abstract

Anemia poses a life-threatening risk to individuals with chronic kidney diseases (CKDs). Insufficient production of erythropoietin (EPO) from the injured kidney is the major reason for anemia, while lack of EPO would further aggravate the kidney injury and make a “vicious cycle.” In this study, we dissected the change of endogenous EPO signaling in the injured kidney by spatial transcriptomic analysis and validated the dual beneficial effects of local recombinant EPO administration on both anemia correction and kidney protection. Next, we constructed an injury-responsive EPO-producing (iREP) element to sense the kidney damage signal and drive the synthesis and secretion of native EPO. After intrarenal implantation of iREP-engineered HEK–293T embryonic kidney cells, the mouse kidney would automatically produce more EPO when sensing injury signal, which in turn enhanced red blood cell count and protected the kidney from further injury. Moreover, we cloned urine-derived SOX9+ epithelial cells (USCs) from healthy donors. The USCs can be transplanted into mouse kidneys, which makes them an alternative candidate cell for iREP engineering. Altogether, the current work proposed a potential approach based on an engineered “smart” cell to treat CKDs.

References

[1] W. Mcclellan, S. L. Aronoff, W. K. Bolton, et al., “The Prevalence of Anemia in Patients With Chronic Kidney Disease,” Current Medical Research and Opinion 20, no. 9 (2004): 1501-1510.

[2] M. A. Atkinson and B. Warady, “Anemia in chronic kidney disease,” Pediatric Nephrology 33, no. 2 (2018): 227-238.

[3] S. M. Koshy and D. F. Geary, “Anemia in children with chronic kidney disease,” Pediatric Nephrology 23, no. 2 (2008): 209-219.

[4] B. K. Kragesteen, A. Giladi, E. David, et al., “The Transcriptional and Regulatory Identity of Erythropoietin Producing Cells,” Nature Medicine 29, no. 5 (2023): 1191-1200.

[5] W. Jelkmann, “Regulation of Erythropoietin Production,” The Journal of Physiology 589, no. Pt 6 (2011): 1251-1258.

[6] A. Hayat, D. Haria, and M. O. Salifu, “Erythropoietin Stimulating Agents in the Management of Anemia of Chronic Kidney Disease,” Patient Prefer Adherence 2 (2008): 195-200.

[7] S. Thavarajah and M. J. Choi, “The Use of Erythropoiesis-Stimulating Agents in Patients with CKD and Cancer: A Clinical Approach,” American Journal of Kidney Diseases 74, no. 5 (2019): 667-674.

[8] T. Nemoto, N. Yokota, W. F. Keane, and H. Rabb, “Recombinant Erythropoietin Rapidly Treats Anemia in Ischemic Acute Renal Failure,” Kidney International 59, no. 1 (2001): 246-251.

[9] J. C. Penny-Dimri, A. D. Cochrane, L. A. Perry, and J. A. Smith, “Characterising the Role of Perioperative Erythropoietin for Preventing Acute Kidney Injury After Cardiac Surgery: Systematic Review and Meta-Analysis,” Heart, Lung and Circulation 25, no. 11 (2016): 1067-1076.

[10] E. Régulier, B. L. Schneider, N. Déglon, Y. Beuzard, and P. Aebischer, “Continuous Delivery of human and Mouse Erythropoietin in Mice by Genetically Engineered Polymer Encapsulated Myoblasts,” Gene Therapy 5, no. 8 (1998): 1014-1022.

[11] D. Bohl, N. Naffakh, and J. M. Heard, “Long-term Control of Erythropoietin Secretion by Doxycycline in Mice Transplanted With Engineered Primary Myoblasts,” Nature Medicine 3, no. 3 (1997): 299-305.

[12] N. S. Patel, E. J. Sharples, S. Cuzzocrea, et al., “Pretreatment With EPO Reduces the Injury and Dysfunction Caused by Ischemia/Reperfusion in the Mouse Kidney in Vivo,” Kidney International 66, no. 3 (2004): 983-989.

[13] E. J. Sharples, N. Patel, P. Brown, et al., “Erythropoietin Protects the Kidney Against the Injury and Dysfunction Caused by Ischemia-reperfusion,” Journal of the American Society of Nephrology: JASN 15, no. 8 (2004): 2115-2124.

[14] D. H. Kang, E. Y. Park, E. S. Yu, Y. S. Lee, and K. I. Yoon, “Renoprotective Effect of Erythropoietin (EPO): Possibly via an Amelioration of Renal Hypoxia With Stimulation of Angiogenesis in the Kidney,” Kidney International 67, no. 5 (2005): 1683.

[15] N. Casadevall, J. Nataf, B. Viron, A. Kolta, and P. Mayeux, “Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin,” The New England Journal of Medicine 16, no. 7 (2002): 329-330.

[16] E. Erek, G. Süleymanlar, and K. Serdengeçti, “Nephrology, Dialysis and Transplantation in Turkey,” Nephrology, Dialysis, Transplantation 17, no. 12 (2002): 2087-2093.

[17] M. Tonelli, W. C. Winkelmayer, K. K. Jindal, W. F. Owen, and B. J. Manns, “The Cost-effectiveness of Maintaining Higher Hemoglobin Targets With Erythropoietin in Hemodialysis Patients,” Kidney International 64, no. 1 (2003): 295-304.

[18] E. Moore and R. Bellomo, “Erythropoietin (EPO) in Acute Kidney Injury,” Annals of Intensive Care 1, no. 1 (2011): 3.

[19] S. Kumar, “Cellular and Molecular Pathways of Renal Repair After Acute Kidney Injury,” Kidney International 93, no. 1 (2018): 27-40.

[20] S. Aggarwal, Z. Wang, D. Rincon Fernandez Pacheco, et al., “SOX9 switch Links Regeneration to Fibrosis at the Single-cell Level in Mammalian Kidneys,” Science (New York, NY) 383, no. 6685 (2024): eadd6371.

[21] J. Y. Kim, Y. Bai, L. A. Jayne, et al., “A Kinome-wide Screen Identifies a CDKL5-SOX9 Regulatory Axis in Epithelial Cell Death and Kidney Injury,” Nature Communications 11, no. 1 (2020): 1924.

[22] J. Liu, F. Yang, Y. Waheed, S. Li, K. Liu, and X. Zhou, “The Role of Roxadustat in Chronic Kidney Disease Patients Complicated With Anemia,” The Korean Journal of Internal Medicine 38, no. 2 (2023): 147-156.

[23] J. L. Babitt and H. Y. Lin, “Mechanisms of Anemia in CKD,” Journal of the American Society of Nephrology: JASN 23, no. 10 (2012): 1631-1634.

[24] M. Brines, G. Grasso, F. Fiordaliso, et al., “Erythropoietin Mediates Tissue Protection Through an Erythropoietin and Common Beta-subunit Heteroreceptor,” Proceedings of the National Academy of Sciences of the United States of America 101, no. 41 (2004): 14907-14912.

[25] C. Yang, H. Xu, D. Yang, et al., “A Renal YY1-KIM1-DR5 Axis Regulates the Progression of Acute Kidney Injury,” Nature Communications 14, no. 1 (2023): 4261.

[26] W. K. Han, V. Bailly, R. Abichandani, R. Thadhani, and J. V. Bonventre, “Kidney Injury Molecule-1 (KIM-1): A Novel Biomarker for human Renal Proximal Tubule Injury,” Kidney International 62, no. 1 (2002): 237-244.

[27] Y. Mori, A. K. Ajay, J. H. Chang, et al., “KIM-1 Mediates Fatty Acid Uptake by Renal Tubular Cells to Promote Progressive Diabetic Kidney Disease,” Cell Metabolism 33, no. 5 (2021): 1042-1061.e7.

[28] J. V. Bonventre, “Kidney Injury Molecule-1 (KIM-1): A Specific and Sensitive Biomarker of Kidney Injury,” Scandinavian Journal of Clinical and Laboratory Investigation 68, no. sup241 (2008): 78-83.

[29] J. Y. Kim, J. A. Silvaroli, G. V. Martinez, et al., “Zinc Finger Protein 24-dependent Transcription Factor SOX9 Up-regulation Protects Tubular Epithelial Cells During Acute Kidney Injury,” Kidney International 103, no. 6 (2023): 1093-1104.

[30] W. Zhang, C. Gao, A. Tsilosani, R. Samarakoon, R. Plews, and P. J. Higgins, “Potential Renal Stem/Progenitor Cells Identified by in Vivo Lineage Tracing,” American Journal of Physiology Renal Physiology 322, no. 4 (2022): F379-f391.

[31] S. Kumar, J. Liu, P. Pang, et al., “Sox9 Activation Highlights a Cellular Pathway of Renal Repair in the Acutely Injured Mammalian Kidney,” Cell Reports 12, no. 8 (2015): 1325-1338.

[32] Q. Ma, Y. Wang, T. Zhang, and W. Zuo, “Notch-mediated Sox9+ Cell Activation Contributes to Kidney Repair After Partial Nephrectomy,” Life Sciences 193 (2018): 104-109.

[33] H. M. Kang, S. Huang, K. Reidy, S. H. Han, F. Chinga, and K. Susztak, “Sox9-Positive Progenitor Cells Play a Key Role in Renal Tubule Epithelial Regeneration in Mice,” Cell Reports 14, no. 4 (2016): 861-871.

[34] H. M. Costello, J. G. Johnston, A. Juffre, G. R. Crislip, and M. L. Gumz, “Circadian Clocks of the Kidney: Function, Mechanism, and Regulation,” Physiological Reviews 102, no. 4 (2022): 1669-1701.

[35] H. Cheng, H. Huang, Z. Guo, Y. Chang, and Z. Li, “Role of Prostaglandin E2 in Tissue Repair and Regeneration,” Theranostics 11, no. 18 (2021): 8836-8854.

[36] A. Kurtz, “Renin Release: Sites, Mechanisms, and Control,” Annual Review of Physiology 73 (2011): 377-399.

[37] H. Gong, W. Wang, T. H. Kwon, et al., “EPO and Alpha-MSH Prevent Ischemia/Reperfusion-induced Down-regulation of AQPs and Sodium Transporters in Rat Kidney,” Kidney International 66, no. 2 (2004): 683-695.

[38] A. C. Webster, E. V. Nagler, R. L. Morton, and P. Masson, “Chronic Kidney Disease,” Lancet (London, England) 389, no. 10075 (2017): 1238-1252.

[39] F. H. Bahlmann, R. Song, S. M. Boehm, et al., “Low-dose Therapy With the Long-acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure,” Circulation 110, no. 8 (2004): 1006-1012.

[40] M. Aoun, G. Sleilaty, C. Boueri, et al., “Erythropoietin in Acute Kidney Injury (EAKI): A Pragmatic Randomized Clinical Trial,” BMC Nephrology 23, no. 1 (2022): 100.

[41] A. Ramzy, D. M. Thompson, K. A. Ward-Hartstonge, et al., “Implanted Pluripotent Stem-cell-derived Pancreatic Endoderm Cells Secrete Glucose-responsive C-peptide in Patients With Type 1 Diabetes,” Cell Stem Cell 28, no. 12 (2021): 2047-2061.e5.

[42] A. M. J. Shapiro, D. Thompson, T. W. Donner, et al., “Insulin Expression and C-peptide in Type 1 Diabetes Subjects Implanted With Stem Cell-derived Pancreatic Endoderm Cells in an Encapsulation Device,” Cell Reports Medicine 2, no. 12 (2021): 100466.

[43] Y. Du, Z. Liang, S. Wang, et al., “Human Pluripotent Stem-cell-derived Islets Ameliorate Diabetes in Non-human Primates,” Nature Medicine 28, no. 2 (2022): 272-282.

[44] Z. Liang, D. Sun, S. Lu, et al., “Implantation Underneath the Abdominal Anterior Rectus Sheath Enables Effective and Functional Engraftment of Stem-cell-derived Islets,” Nature Metabolism 5, no. 1 (2023): 29-40.

[45] T. Yokoo, A. Fukui, K. Matsumoto, et al., “Generation of a Transplantable Erythropoietin-producer Derived From human Mesenchymal Stem Cells,” Transplantation 85, no. 11 (2008): 1654-1658.

[46] H. Gurruchaga, J. Ciriza, L. Saenz del Burgo, et al., “Cryopreservation of Microencapsulated Murine Mesenchymal Stem Cells Genetically Engineered to Secrete Erythropoietin,” International Journal of Pharmaceutics 485, no. 1 (2015): 15-24.

[47] N. Eliopoulos, R. F. Gagnon, M. Francois, and J. Galipeau, “Erythropoietin Delivery by Genetically Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice With Chronic Renal Failure,” Journal of the American Society of Nephrology 17, no. 6 (2006): 1576-1584.

[48] M. Estiri, B. Estiri, A. Fallah, et al., “Therapeutic Effects of Mesenchymal Stem Cells Expressing Erythropoietin on Cancer-Related Anemia in Mice Model,” Current Gene Therapy 22, no. 5 (2022): 406-416.

[49] P. M. Campeau, M. Rafei, M. François, E. Birman, K. A. Forner, and J. Galipeau, “Mesenchymal Stromal Cells Engineered to Express Erythropoietin Induce Anti-erythropoietin Antibodies and Anemia in Allorecipients,” Molecular Therapy: the Journal of the American Society of Gene Therapy 17, no. 2 (2009): 369-372.

[50] H. Y. Choi, T. Y. Kim, M. Lee, et al., “Kidney Mesenchymal Stem Cell-derived Extracellular Vesicles Engineered to Express Erythropoietin Improve Renal Anemia in Mice With Chronic Kidney Disease,” Stem Cell Reviews and Reports 18, no. 3 (2022): 980-992.

[51] J. Chen, W. L. Yang, G. Li, et al., “Transfection of mEpo Gene to Intestinal Epithelium in Vivo Mediated by Oral Delivery of Chitosan-DNA Nanoparticles,” World Journal of Gastroenterology 10, no. 1 (2004): 112-116.

[52] E. Régulier, B. L. Schneider, N. Déglon, Y. Beuzard, and P. Aebischer, “Continuous Delivery of human and Mouse Erythropoietin in Mice by Genetically Engineered Polymer Encapsulated Myoblasts,” Gene Therapy 5, no. 8 (1998): 1014-1022.

[53] S. J. Korsmeyer, “BCL-2 Gene family and the Regulation of Programmed Cell Death,” Cancer Research 59, no. 7 Suppl (1999): 1693s-1700s.

[54] H. Nie, Z. Zhao, D. Zhou, et al., “Activated SOX9+ Renal Epithelial Cells Promote Kidney Repair Through Secreting Factors,” Cell Proliferation 56, no. 4 (2023): e13394.

[55] Y. Q. Zhou, Y. Shi, L. Yang, et al., “Genetically Engineered Distal Airway Stem Cell Transplantation Protects Mice From Pulmonary Infection,” EMBO Molecular Medicine 12, no. 1 (2020): e10233.

[56] C. Wang, N. Li, Y. Li, et al., “Engineering a HEK-293T Exosome-based Delivery Platform for Efficient Tumor-targeting Chemotherapy/Internal Irradiation Combination Therapy,” Journal of Nanobiotechnology 20, no. 1 (2022): 247.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.